相关实验视频

Updated: Jun 19, 2025

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

高特异性SARS-CoV-2主蛋白酶 (M^pro) 突变对抗在安全的,基于VSV的系统中选择的临床抗病毒恩西特雷尔维尔

Stefanie Rauch¹, Francesco Costacurta¹, Helge Schöppe²

¹Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Antiviral research

|July 25, 2024

概括

研究人员开发了一个安全的系统来研究针对SARS-CoV-2的抗病毒耐药性突变. 这项研究确定了赋予对恩西特里尔维尔耐药性的特定突变,同时保持对尼尔马特里尔维尔的敏感性,有助于疫情准备.

科学领域:

病毒学病毒学
药物发现药物发现药物发现
分子生物学分子生物学

背景情况:

两个关键的SARS-CoV-2抗病毒药物,尼尔马特里尔维尔/里托纳维尔 (Paxlovid) 和恩西特里尔维尔 (Xocova),是有效的蛋白酶抑制剂.
抗微生物药物耐药性是有效治疗和流行病准备的重大挑战.
为研究生成耐药病毒引发了安全问题,特别是对于像SARS-CoV-2这样的流行病原体.

研究的目的:

开发一种安全的方法来研究SARS-CoV-2抗病毒耐药性突变.
为了识别和描述赋予对恩西特里尔病毒耐药性的突变.
为了比较ensitrelvir和nirmatrelvir的耐药性概况.

主要方法:

使用了依赖于SARS-CoV-2主要蛋白酶 (VSV-Mpro) 的安全的嵌合体囊泡性口腔炎病毒系统.
通过用药物对VSV-Mpro系统进行治疗,选择了对恩西特里尔维尔耐药的突变.
使用酶分析和SARS-CoV-2复制品确认了选择性突变.

主要成果:

通过使用VSV-Mpro系统,成功选择了高度特定的对恩西特雷尔维尔耐药突变物.
选择的突变仍然在很大程度上对nirmatrelvir. vir敏感.
通过酶分析和复制体研究验证了对恩西特里尔维尔特异性的突变.

结论:

开发的VSV-Mpro系统为研究抗病毒耐药性提供了一个安全的替代方案.
恩西特里尔维尔和尼尔马特里尔维尔表现出不同的病毒耐药性概况.
了解这些独特的耐药性概况对于指导治疗决策和未来的流行病准备至关重要.

关键词:

3CL ((支持) 的) 支持者抗病毒药物抗病毒药物恩西特里尔维尔 (Ensitrelvir) 是一种更多的是为) 支持)尼尔马特里尔维尔 (Nirmatrelvir) 是一种帕克斯洛维的使用方法电阻电阻电阻电阻电阻电阻在S-21762222中使用.这就是SARS-CoV-2病毒.基于VSV的电阻选择.在 Xocovaova 的位置上.在NSP5中,nsp5是什么?

更多相关视频

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

相关概念视频

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...